As a result, in order for Vit-C to restore TET2 activity, significant levels of SLC2A3 expression are required [192]; suggesting that SLC2A3 might be a successful biomarker to predict how well Vit-C therapy might work in AML. Here, TET2 is linked to acute myeloid leukemia.